Maintenance therapy with ribavirin in patients with chronic hepatitis C who fail to respond to combination therapy with interferon alfa and ribavirin

Hepatology

Volumn 38, Issue 1, 2003, Pages 66-74

  Hoofnagle, Jay H ^a,b   Ghany, Marc G ^a   Kleiner, David E ^c   Doo, Edward ^a   Heller, Theo ^a   Promrat, Kittichai ^a   Ong, Janus ^a   Khokhar, Farooq ^a   Soza, Alejandro ^a   Herion, David ^a   Park, Yoon ^a   Everhart, James E ^b   Liang, T Jake ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; AMINOTRANSFERASE; HEPATITIS C VIRUS RNA; PLACEBO; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; UNCLASSIFIED DRUG; VIRUS DNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; BLOOD CELL COUNT; CHRONIC HEPATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MIXTURE; DRUG SAFETY; FATIGUE; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; INFLAMMATION; LIVER BIOPSY; LIVER FIBROSIS; LIVER NECROSIS; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PRURITUS; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; VISUAL ANALOG SCALE;

EID: 0038122772     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2003.50258     Document Type: Article

References (30)

1. McHutchinson JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, et al, for the Hepatitis Interventional Therapy Group. Interferon alfa 2-b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998;339:1485-1492.
2. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, et al, for the International Hepatitis Interventional Therapy Group. Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998;352:1426-1432.
3. Liang TJ, Reherman B, Seeff LB, Hoofnagle JH. Pathogenesis, natural history, treatment and prevention of hepatitis C. Ann Intern Med 2000;132:296-305.
4. Lau DTY, Kleiner DE, Ghany MG, Park Y, Schmid P, Hoofnagle JH. 10-year follow-up after interferon-alpha therapy for chronic hepatitis C. HEPATOLOGY 1998;28:1121-1127.
5. Marcellin P, Boyer N, Gervais A, Martinot M, Pouteau M, Castelnau C, Kilani A, et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med 1997;127:875-881.
6. Shiratori Y, Imazeki F, Moriyama M, Yano M, Arakawa Y, Yokosuka O, Kuroki T, et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000;132:517-524.
7. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized controlled trial. Lancet 2001;358:958-965.
8. Fried MW, Shiffman ML, Reddy RK, Smith C, Marinos G, Goncales G Jr, Häussinger D, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-982.
9. Di Bisceglie AM, Hoofnagle JH. Optimal therapy of hepatitis C. HEPATOLOGY 2002;36(Suppl 1):S121-S127.
10. Seeff LB. Natural history of chronic hepatitis C. HEPATOLOGY 2002;36(Suppl 1):S35-S46.
11. Rodger AJ, Roberts S, Lanigan A, Bowden S, Brown T, Crofts N. Assessment of long-term outcomes of community-acquired hepatitis C in a cohort with sera stored from 1971-75. HEPATOLOGY 2000;32:582-587.
12. Anonymous. This month from the NIH: the HALT-C Trial. HEPATOLOGY 2002;36:792-793.
13. Di Bisceglie AM, Conjeevarum HS, Fried MW, Sallie R, Park Y, Yurdaydin C, Swain M, et al. Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995;123:897-903.
14. Dusheiko G, Main J, Thomas H, Reichard O, Lee C, Dhillon A, Rassam S, et al. Ribavirin treatment for patients with chronic hepatitis C: results of a randomized-controlled study. J Hepatol 1996;25:591-598.
15. Bodenheimer HC Jr, Lindsay KL, Davis GL, Lewis JH, Thung SN, Seeff LB. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. HEPATOLOGY 1997;26:473-477.
16. Hoofnagle JH, Lau D, Conjeevaram H, Kleiner D, Di Bisceglie AM. Prolonged therapy of chronic hepatitis C with ribavirin. J Viral Hepat 1996;3:247-252.
17. Durand JM, Cacoub P, Lunel-Fabiani F, Cosserat J, Cretel E, Kaplanski G, Frances C, et al. Ribavirin in hepatitis C related cryoglobulinemia. J Rheumatol 1998;25:1115-1117.
18. Bizollon T, Palazzo U, Ducerf C, Chevallier M, Elliott M, Baulieux J, Pouyet M, et al. Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation. HFPATOLOGY 1997;26:500-504.
19. desmet v, gerber m, hoofnagle jh, manns m, scheuer P. Classification of chronic hepatitis: diagnosis, grading and staging. HEPATOLOGY 1994;19:1513-1520.
20. Shakil AO, Contry-Cantilena C, Alter HJ, Hayashi P, Kleiner DE, Tedeschi V, Krawczynski K, et al. Volunteer blood donors with antibody to hepatitis C virus: clinical, biochemical, virologic, and histologic features. Ann Intern Med 1995;123:330-337.
21. Ishak K, Baptista A, Bianchi L, Callea F, DeGroote J, Gudat F, Denk H, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696-699.
22. Johnson EM. The effects of ribavirin on developmental reproduction: a critical review of published and unpublished studies in expetimental animals. J Am Coll Toxicol 1990;9:551-556.
23. Di Bisceglie AM, Bacon BR, Kleiner DE, Hoofnagle JH. Increase in hepatic iron stores following prolonged therapy with ribavirin in patients with chronic hepatitis C. J Hepatol 1994;21:1109-1112.
24. Fried MW. Side effects of therapy of hepatitis C and their management. HEPATOLOGY 2002;36(Suppl 1):S237-S244.
25. Martinot-Peignoux M, Boyer N, Cazals-Hatem D, Pham BN, Gervais A, Le Breton V, Levy S, et al. Prospective study on anti-hepatitis C virus-positive patients with persistently normal serum alanine transaminase with or without detectable serum hepatitis C virus RNA. HEPATOLOGY 2001;34:1000-1005.
26. Fattovich G, Giustina G, Degos F, Diodati G, Tremolada F, Nevens F, Almasio P, et al. Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. J Hepatol 1997;27:201-205.
27. Omata M, Shiratori Y. Long-term effects of interferon therapy on histology and development of hepatocellular carcinoma in hepatitis C. J Gastroenterol Hepatol 2000;15:134-140.
28. Shindo M, Hamada K, Oda Y, Okuno T. Long-term follow-up study of sustained biochemical responders with interferon therapy. HEPATOLOGY 2001;33:1299-1302.
29. Querenghi F, Yu Q, Billaud G, Maertens G, Trepo C, Zoulim F. Evolution of hepatitis C virus genome in chronically infected patients receiving ribavirin monotherapy. J Viral Hepat 2001;8:120-131.
30. Lanfotd RE, Chavez D, Guerra B, Lau JY, Hong Z, Brasky KM, Beames B. Ribavirin induces error-prone replication of GB virus B in primary tamarin hepatocytes. J Vitol 2001;75:8074-8081.